The Food and Drug Administration (FDA) has announced a significant recall of a widely used blood pressure medication due to potential cross-contamination issues. Glenmark Pharmaceuticals Inc., based in Elmwood Park, New Jersey, is recalling multiple lots of bisoprolol fumarate and hydrochlorothiazide tablets, marketed under the brand name Ziac.
Details of the Recall
This recall was initiated after testing of retained samples revealed traces of ezetimibe, a cholesterol medication also produced by Glenmark. The recall report was issued on December 1.
Classification and Risk Level
- The FDA classified this recall as a Class III risk. This classification indicates that exposure to the product is unlikely to cause adverse health consequences.
About the Medication
Bisoprolol and hydrochlorothiazide work together to manage hypertension. Bisoprolol blocks beta-1 receptors, helping to normalize heart function, while hydrochlorothiazide aids in removing excess sodium and water from the body. Together, these effects lower blood pressure and reduce the risk of heart attacks and strokes.
Recalled Lots and Their Information
The recalled medication includes various dosages and bottle sizes. Here are the key details:
| Dosage | Bottle Size | Lot Number | Expiration Date |
|---|---|---|---|
| 2.5 mg | 30-tablet bottles | 17232401 | 11/2025 |
| 2.5 mg | 100-tablet bottles | 17232401 | 11/2025 |
| 2.5 mg | 500-tablet bottles | 17232401, 17240974 | 11/2025, 05/2026 |
Next Steps for Consumers
Glenmark Pharmaceuticals has yet to provide specific guidance concerning the recalled medications. However, GoodRx recommends that individuals find the lot number on their bottles, consult their pharmacist and healthcare provider, and safely dispose of any affected tablets.
